FRINK Linked Data Fragments server

Matches in SemOpenAlex for { <https://semopenalex.org/work/W2802034996> ?p ?o ?g. }

• W2802034996 endingPage "4214" @default.
• W2802034996 startingPage "4201" @default.
• W2802034996 abstract "Purpose: Loss of cell-cycle control is a hallmark of cancer, which can be targeted with agents, including cyclin-dependent kinase-4/6 (CDK4/6) kinase inhibitors that impinge upon the G1-S cell-cycle checkpoint via maintaining activity of the retinoblastoma tumor suppressor (RB). This class of drugs is under clinical investigation for various solid tumor types and has recently been FDA-approved for treatment of breast cancer. However, development of therapeutic resistance is not uncommon.Experimental Design: In this study, palbociclib (a CDK4/6 inhibitor) resistance was established in models of early stage, RB-positive cancer.Results: This study demonstrates that acquired palbociclib resistance renders cancer cells broadly resistant to CDK4/6 inhibitors. Acquired resistance was associated with aggressive in vitro and in vivo phenotypes, including proliferation, migration, and invasion. Integration of RNA sequencing analysis and phosphoproteomics profiling revealed rewiring of the kinome, with a strong enrichment for enhanced MAPK signaling across all resistance models, which resulted in aggressive in vitro and in vivo phenotypes and prometastatic signaling. However, CDK4/6 inhibitor-resistant models were sensitized to MEK inhibitors, revealing reliance on active MAPK signaling to promote tumor cell growth and invasion.Conclusions: In sum, these studies identify MAPK reliance in acquired CDK4/6 inhibitor resistance that promotes aggressive disease, while nominating MEK inhibition as putative novel therapeutic strategy to treat or prevent CDK4/6 inhibitor resistance in cancer. Clin Cancer Res; 24(17); 4201-14. ©2018 AACR." @default.
• W2802034996 created "2018-05-17" @default.
• W2802034996 creator A5010444377 @default.
• W2802034996 creator A5013798827 @default.
• W2802034996 creator A5016505833 @default.
• W2802034996 creator A5024865103 @default.
• W2802034996 creator A5033796700 @default.
• W2802034996 creator A5035025572 @default.
• W2802034996 creator A5041126882 @default.
• W2802034996 creator A5042472942 @default.
• W2802034996 creator A5057059030 @default.
• W2802034996 creator A5062007054 @default.
• W2802034996 creator A5065104688 @default.
• W2802034996 creator A5071840998 @default.
• W2802034996 creator A5074168992 @default.
• W2802034996 creator A5074656098 @default.
• W2802034996 creator A5078344568 @default.
• W2802034996 creator A5080479676 @default.
• W2802034996 creator A5090355173 @default.
• W2802034996 date "2018-09-01" @default.
• W2802034996 modified "2023-10-12" @default.
• W2802034996 title "MAPK Reliance via Acquired CDK4/6 Inhibitor Resistance in Cancer" @default.
• W2802034996 cites W1578291413 @default.
• W2802034996 cites W1833796513 @default.
• W2802034996 cites W1967774964 @default.
• W2802034996 cites W1967789049 @default.
• W2802034996 cites W1967902354 @default.
• W2802034996 cites W1984245506 @default.
• W2802034996 cites W1993624611 @default.
• W2802034996 cites W2003309405 @default.
• W2802034996 cites W2020541351 @default.
• W2802034996 cites W2029575024 @default.
• W2802034996 cites W2040564571 @default.
• W2802034996 cites W2046799619 @default.
• W2802034996 cites W2080752012 @default.
• W2802034996 cites W2107633226 @default.
• W2802034996 cites W2112431155 @default.
• W2802034996 cites W2121103946 @default.
• W2802034996 cites W2134626691 @default.
• W2802034996 cites W2135581618 @default.
• W2802034996 cites W2137267184 @default.
• W2802034996 cites W2150926065 @default.
• W2802034996 cites W2152095891 @default.
• W2802034996 cites W2159686118 @default.
• W2802034996 cites W2161112598 @default.
• W2802034996 cites W2164575467 @default.
• W2802034996 cites W2166229764 @default.
• W2802034996 cites W2179438025 @default.
• W2802034996 cites W2219112405 @default.
• W2802034996 cites W2300472255 @default.
• W2802034996 cites W2309969893 @default.
• W2802034996 cites W2345781825 @default.
• W2802034996 cites W2407627822 @default.
• W2802034996 cites W2460832567 @default.
• W2802034996 cites W2475269618 @default.
• W2802034996 cites W2494960642 @default.
• W2802034996 cites W2502300311 @default.
• W2802034996 cites W2520255934 @default.
• W2802034996 cites W2530482928 @default.
• W2802034996 cites W2537675006 @default.
• W2802034996 cites W2549441121 @default.
• W2802034996 cites W2573966335 @default.
• W2802034996 cites W2583538213 @default.
• W2802034996 cites W2593997731 @default.
• W2802034996 cites W2598063839 @default.
• W2802034996 cites W2602224308 @default.
• W2802034996 cites W2771355810 @default.
• W2802034996 cites W2775259666 @default.
• W2802034996 cites W2795063553 @default.
• W2802034996 cites W2923498804 @default.
• W2802034996 cites W4234586755 @default.
• W2802034996 doi "https://doi.org/10.1158/1078-0432.ccr-18-0410" @default.
• W2802034996 hasPubMedCentralId "https://www.ncbi.nlm.nih.gov/pmc/articles/6125187" @default.
• W2802034996 hasPubMedId "https://pubmed.ncbi.nlm.nih.gov/29739788" @default.
• W2802034996 hasPublicationYear "2018" @default.
• W2802034996 type Work @default.
• W2802034996 sameAs 2802034996 @default.
• W2802034996 citedByCount "73" @default.
• W2802034996 countsByYear W28020349962018 @default.
• W2802034996 countsByYear W28020349962019 @default.
• W2802034996 countsByYear W28020349962020 @default.
• W2802034996 countsByYear W28020349962021 @default.
• W2802034996 countsByYear W28020349962022 @default.
• W2802034996 countsByYear W28020349962023 @default.
• W2802034996 crossrefType "journal-article" @default.
• W2802034996 hasAuthorship W2802034996A5010444377 @default.
• W2802034996 hasAuthorship W2802034996A5013798827 @default.
• W2802034996 hasAuthorship W2802034996A5016505833 @default.
• W2802034996 hasAuthorship W2802034996A5024865103 @default.
• W2802034996 hasAuthorship W2802034996A5033796700 @default.
• W2802034996 hasAuthorship W2802034996A5035025572 @default.
• W2802034996 hasAuthorship W2802034996A5041126882 @default.
• W2802034996 hasAuthorship W2802034996A5042472942 @default.
• W2802034996 hasAuthorship W2802034996A5057059030 @default.
• W2802034996 hasAuthorship W2802034996A5062007054 @default.
• W2802034996 hasAuthorship W2802034996A5065104688 @default.
• W2802034996 hasAuthorship W2802034996A5071840998 @default.
• W2802034996 hasAuthorship W2802034996A5074168992 @default.

• next